MitoChem Therapeutics develops treatments to address the effects of mitochondrial dysfunction in neurodegenerative, aging, and disease.
MitoChem Therapeutics has raised $200K in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in September 2022.
MitoChem Therapeutics's investors include South Carolina Research Authority, Foundation Fighting Blindness, SC Launch, Inc., Ichor Life Sciences.
MitoChem Therapeutics is headquartered in Charleston, United States.
MitoChem Therapeutics develops treatments to address the effects of mitochondrial dysfunction in neurodegenerative, aging, and disease.
MitoChem Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"MitoChem Therapeutics — Funding & Investors." VCBacked, September 6, 2022, https://www.vcbacked.co/company/mitochem-therapeutics. Accessed November 14, 2026.
VCBacked. (2022). MitoChem Therapeutics — Funding & Investors. Retrieved November 14, 2026, from https://www.vcbacked.co/company/mitochem-therapeutics
{{cite web |title=MitoChem Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/mitochem-therapeutics |website=VCBacked |access-date=November 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at MitoChem Therapeutics? Request a listing update